147 related articles for article (PubMed ID: 20519697)
1. CYP3AP1*3 allele is associated with lipid-lowering efficacy of simvastatin and atorvastatin in Chinese women.
Li YP; Zhang LR; Jia M; Hu XJ
J Clin Pharmacol; 2011 Feb; 51(2):181-8. PubMed ID: 20519697
[TBL] [Abstract][Full Text] [Related]
2. Lack of association between SLCO1B1 polymorphism and the lipid-lowering effects of atorvastatin and simvastatin in Chinese individuals.
Fu Q; Li YP; Gao Y; Yang SH; Lu PQ; Jia M; Zhang LR
Eur J Clin Pharmacol; 2013 Jun; 69(6):1269-74. PubMed ID: 23263738
[TBL] [Abstract][Full Text] [Related]
3. Comments on "CYP3AP1*3 allele is associated with lipid-lowering efficacy of simvastatin and atorvastatin in Chinese women".
Hu M; Mak VW; Tomlinson B
J Clin Pharmacol; 2012 Nov; 52(11):1768-9; author reply 1770-1. PubMed ID: 23105125
[No Abstract] [Full Text] [Related]
4. CYP3A4*1G polymorphism is associated with lipid-lowering efficacy of atorvastatin but not of simvastatin.
Gao Y; Zhang LR; Fu Q
Eur J Clin Pharmacol; 2008 Sep; 64(9):877-82. PubMed ID: 18528690
[TBL] [Abstract][Full Text] [Related]
5. Interactions between CYP7A1 A-204C and ABCG8 C1199A polymorphisms on lipid lowering with atorvastatin.
Wei KK; Zhang LR; Zhang Y; Hu XJ
J Clin Pharm Ther; 2011 Dec; 36(6):725-33. PubMed ID: 21128988
[TBL] [Abstract][Full Text] [Related]
6. Interactions between CYP3A5*3 and POR*28 polymorphisms and lipid lowering response with atorvastatin.
Wei KK; Zhang LR
Clin Drug Investig; 2015 Sep; 35(9):583-91. PubMed ID: 26293521
[TBL] [Abstract][Full Text] [Related]
7. Ile118Val genetic polymorphism of CYP3A4 and its effects on lipid-lowering efficacy of simvastatin in Chinese hyperlipidemic patients.
Wang A; Yu BN; Luo CH; Tan ZR; Zhou G; Wang LS; Zhang W; Li Z; Liu J; Zhou HH
Eur J Clin Pharmacol; 2005 Feb; 60(12):843-8. PubMed ID: 15650881
[TBL] [Abstract][Full Text] [Related]
8. Lack of association of the p450 oxidoreductase *28 single nucleotide polymorphism with the lipid-lowering effect of statins in hypercholesterolemic patients.
Ragia G; Kolovou V; Tavridou A; Elens L; Tselepis AD; Elisaf M; Van Schaik RH; Kolovou G; Manolopoulos VG
Mol Diagn Ther; 2014 Jun; 18(3):323-31. PubMed ID: 24430948
[TBL] [Abstract][Full Text] [Related]
9. Physicochemical modifications induced by statins therapy on human erythrocytes membranes.
Broncel M; Bała A; Koter-Michalak M; Duchnowicz P; Wojsznis W; Chojnowska-Jezierska J
Wiad Lek; 2007; 60(7-8):321-8. PubMed ID: 18175550
[TBL] [Abstract][Full Text] [Related]
10. Hypocholesterolemic effects of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors in the guinea pig: atorvastatin versus simvastatin.
Conde K; Pineda G; Newton RS; Fernandez ML
Biochem Pharmacol; 1999 Oct; 58(7):1209-19. PubMed ID: 10484079
[TBL] [Abstract][Full Text] [Related]
11. Common variants of HMGCR, CETP, APOAI, ABCB1, CYP3A4, and CYP7A1 genes as predictors of lipid-lowering response to atorvastatin therapy.
Poduri A; Khullar M; Bahl A; Sehrawat BS; Sharma Y; Talwar KK
DNA Cell Biol; 2010 Oct; 29(10):629-37. PubMed ID: 20578904
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of sexual dimorphism in the efficacy and safety of simvastatin/atorvastatin therapy in a southern Brazilian cohort.
Smiderle L; Lima LO; Hutz MH; Van der Sand CR; Van der Sand LC; Ferreira ME; Pires RC; Almeida S; Fiegenbaum M
Arq Bras Cardiol; 2014 Jul; 103(1):33-40. PubMed ID: 25120083
[TBL] [Abstract][Full Text] [Related]
13. Lipid-lowering response to statins is affected by CYP3A5 polymorphism.
Kivistö KT; Niemi M; Schaeffeler E; Pitkälä K; Tilvis R; Fromm MF; Schwab M; Eichelbaum M; Strandberg T
Pharmacogenetics; 2004 Aug; 14(8):523-5. PubMed ID: 15284534
[TBL] [Abstract][Full Text] [Related]
14. Influence of genetic variation in CYP3A4 and ABCB1 on dose decrease or switching during simvastatin and atorvastatin therapy.
Becker ML; Visser LE; van Schaik RH; Hofman A; Uitterlinden AG; Stricker BH
Pharmacoepidemiol Drug Saf; 2010 Jan; 19(1):75-81. PubMed ID: 19802823
[TBL] [Abstract][Full Text] [Related]
15. A dose-specific meta-analysis of lipid changes in randomized controlled trials of atorvastatin and simvastatin.
Rogers SL; Magliano DJ; Levison DB; Webb K; Clarke PJ; Grobler MP; Liew D
Clin Ther; 2007 Feb; 29(2):242-52. PubMed ID: 17472817
[TBL] [Abstract][Full Text] [Related]
16. CYP7A1 polymorphism influences the LDL cholesterol-lowering response to atorvastatin.
Jiang XY; Zhang Q; Chen P; Li SY; Zhang NN; Chen XD; Wang GC; Wang HB; Zhuang MQ; Lu M
J Clin Pharm Ther; 2012 Dec; 37(6):719-23. PubMed ID: 22882727
[TBL] [Abstract][Full Text] [Related]
17. Hemostatic effects of atorvastatin versus simvastatin.
Kadikoylu G; Yukselen V; Yavasoglu I; Bolaman Z
Ann Pharmacother; 2003 Apr; 37(4):478-84. PubMed ID: 12659599
[TBL] [Abstract][Full Text] [Related]
18. Pitavastatin: novel effects on lipid parameters.
Chapman MJ
Atheroscler Suppl; 2011 Nov; 12(3):277-84. PubMed ID: 22152282
[TBL] [Abstract][Full Text] [Related]
19. Effects of statin treatment on uric acid homeostasis in patients with primary hyperlipidemia.
Milionis HJ; Kakafika AI; Tsouli SG; Athyros VG; Bairaktari ET; Seferiadis KI; Elisaf MS
Am Heart J; 2004 Oct; 148(4):635-40. PubMed ID: 15459594
[TBL] [Abstract][Full Text] [Related]
20. Differential effects of simvastatin and atorvastatin on high-density lipoprotein cholesterol and apolipoprotein A-I are consistent across hypercholesterolemic patient subgroups.
Davidson MH; Ose L; Frohlich J; Scott RS; Dujovne CA; Escobar ID; Bertolami MC; Cihon F; Maccubbin DL; Mercuri M
Clin Cardiol; 2003 Nov; 26(11):509-14. PubMed ID: 14640465
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]